Want to see AU:BDX full AI Analyst Report?
Top Page
BCAL Diagnostics Limited
(Sydney:BDX)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.08
▼(-23.00% Downside)
Action:Downgraded
Date:06/26/26
The score is driven primarily by very weak financial performance, including a steep revenue decline, heavy losses, and negative cash generation. Technical indicators add modest support from near-term stabilization but remain pressured by a negative MACD and price below longer-term moving averages. Valuation contributes negatively because the negative P/E reflects ongoing losses and there is no dividend yield data to offset risk.
Positive Factors
Proprietary diagnostic technology
Owning a proprietary blood-based detection technology is a durable competitive asset: it supports product differentiation, licensing or lab-service margins, and longer-term clinical adoption. If validations progress, IP and platform economics can sustain growth beyond near-term cycles.
Negative Factors
Severe revenue decline
A near-total revenue collapse undermines operational scalability and indicates commercial traction problems or contract loss. Over several months this sharply raises the risk that R&D and validation programs cannot be sustained without new funding or strategic partnership, raising execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary diagnostic technology
Owning a proprietary blood-based detection technology is a durable competitive asset: it supports product differentiation, licensing or lab-service margins, and longer-term clinical adoption. If validations progress, IP and platform economics can sustain growth beyond near-term cycles.
Read all positive factors
BCAL Diagnostics Limited (BDX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$26.91M
Dividend YieldN/A
Average Volume (3M)421.90K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS Growth26.04%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding368,683,300
10 Day Avg. Volume534,308
30 Day Avg. Volume421,904
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.64
Price to Sales (P/S)1047.06
P/FCF Ratio-3.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BCAL Diagnostics Limited Business Overview & Revenue Model
Company Description
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for ...
How the Company Makes Money
null...
BCAL Diagnostics Limited Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.31M | 21.64K | 3.10M | 2.79M | 718.67K | 275.25K |
| Gross Profit | 915.90K | 21.64K | 3.10M | 2.79M | 698.06K | 275.25K |
| EBITDA | -7.74M | -6.19M | -5.67M | -7.72M | -4.06M | -1.80M |
| Net Income | -7.16M | -7.24M | -6.40M | -5.06M | -3.39M | -1.52M |
Balance Sheet | ||||||
| Total Assets | 7.17M | 9.91M | 12.27M | 8.37M | 10.59M | 4.13M |
| Cash, Cash Equivalents and Short-Term Investments | 3.33M | 4.52M | 6.47M | 3.17M | 9.57M | 3.41M |
| Total Debt | 3.78M | 2.38M | 1.52M | 1.06M | 0.00 | 0.00 |
| Total Liabilities | 4.68M | 3.69M | 3.68M | 3.16M | 950.42K | 525.60K |
| Stockholders Equity | 2.50M | 6.22M | 8.59M | 5.21M | 9.64M | 3.61M |
Cash Flow | ||||||
| Free Cash Flow | -6.46M | -6.92M | -5.67M | -6.41M | -7.25M | -1.21M |
| Operating Cash Flow | -5.96M | -6.14M | -4.52M | -6.05M | -3.22M | -1.21M |
| Investing Cash Flow | -196.42K | -787.67K | -1.15M | 3.64M | -4.03M | -3.85K |
| Financing Cash Flow | 2.48M | 4.97M | 8.97M | 13.24K | 9.41M | 4.20M |
BCAL Diagnostics Limited Technical Analysis
Positive
0.10
Price Trends
0.08
Positive
0.09
Negative
0.09
Negative
Market Momentum
>-0.01
Negative
55.45
Neutral
41.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BDX, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.08, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.45 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BDX.
BCAL Diagnostics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$10.50B | 18.92 | 6.39% | 4.69% | 13.14% | -2.73% | |
59 Neutral | AU$414.07M | 15.00 | 16.35% | 4.60% | 1.12% | -12.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$279.57M | -0.50 | -29.48% | ― | -12.15% | -2285.99% | |
45 Neutral | AU$92.55M | -4.82 | -164.12% | ― | -14.85% | -41.04% | |
41 Neutral | AU$33.13M | -4.01 | -476.27% | ― | ― | -142.39% | |
39 Underperform | AU$26.91M | -4.07 | -164.22% | ― | ― | 26.04% |
* Healthcare Sector Average
AU:BDX
BCAL Diagnostics Limited
0.08
0.02
35.00%
AU:HLS
Healius Limited
0.38
-0.37
-49.33%
AU:RHY
Rhythm Biosciences Ltd.
0.09
0.03
49.18%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.09
0.06
200.00%
AU:SHL
Sonic Healthcare Limited
20.93
-5.09
-19.57%
AU:ACL
Australian Clinical Labs Ltd
2.23
-0.42
-15.98%
BCAL Diagnostics Limited Corporate Events
BCAL launches blood test to monitor breast cancer recurrence
Jun 18, 2026
BCAL Diagnostics has unveiled BREASTEST Monitor, a new blood test designed to evaluate women for local breast cancer recurrence after treatment, initially targeting patients aged 50 and above. The company’s platform aims to complement existi...
BCAL Moves Toward U.S. Entry With Sonic Healthcare Validation Deal
May 27, 2026
BCAL Diagnostics has signed a validation agreement with Sonic Healthcare USA to optimise and validate BreastestPlus Version 2 as a Laboratory Developed Test in a CLIA-certified reference laboratory in Austin, Texas. The collaboration targets entry...
BCAL taps industry veteran Anne-Louise Arnett to spearhead cancer diagnostics rollout
May 10, 2026
BCAL Diagnostics has appointed seasoned medical technology executive Anne-Louise (Annie) Arnett as chief executive officer from 1 June 2026, tasking her with accelerating the company’s commercial roadmap and international expansion. Arnett, ...
BCAL accelerates national rollout of cancer blood tests and prepares next-gen breast screening launch
Apr 21, 2026
BCAL Diagnostics reported progress on the national rollout of its Avantect pancreatic and ovarian blood tests, now available through Sonic Healthcare and Healius pathology networks, generating $88,000 in third-quarter revenue from 91 tests. A new ...
BCAL seeks Medicare backing for Avantect pancreatic cancer blood test
Mar 31, 2026
BCAL Diagnostics has lodged an application with the Medical Services Advisory Committee seeking Medicare Benefits Schedule reimbursement for its Avantect Pancreatic Cancer Test, aiming to make the blood-based assay more broadly accessible to high-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.